Bonanni Paolo, Malcarne Michela, Moro Francesca, Veggiotti Pierangelo, Buti Daniela, Ferrari Anna Rita, Parrini Elena, Mei Davide, Volzone Anna, Zara Federico, Heron Sarah E, Bordo Laura, Marini Carla, Guerrini Renzo
Epilepsy, Neurophysiology, Neurogenetics Unit, IRCCS Fondazione Stella Maris, Pisa, Italy.
Epilepsia. 2004 Feb;45(2):149-58. doi: 10.1111/j.0013-9580.2004.04303.x.
We describe seven Italian families with generalized epilepsy with febrile seizures plus (GEFS+), in which mutations of SCN1A, SCN1B, and GABRG2 genes were excluded and compare their clinical spectrum with that of previously reported GEFS+ with known mutations.
We performed a clinical study of seven families (167 individuals). The molecular study included analysis of polymerase chain reaction (PCR) fragments of SCN1A and SCN1B exons by denaturing high-performance liquid chromatography (DHPLC) and direct sequencing of GABRG2 in all families. We excluded SCN1A, SCN1B, and GABRG2 genes with linkage analysis in a large pedigree and directly sequenced SCN2A in a family with neonatal-infantile seizures onset. We compared the epilepsy phenotypes observed in our families with those of GEFS+ families harboring mutations of SCN1A, SCN1B, and GABRG2 and estimated the percentage of mutations of these genes among GEFS+ cases by reviewing all published studies.
Inheritance was autosomal dominant with 69% penetrance. Forty-one individuals had epilepsy: 29 had a phenotype consistent with GEFS+; seven had idiopathic generalized epilepsy (IGE); in three, the epilepsy type could not be classified; and two were considered phenocopies. Clinical phenotypes included FS+ (29.2%), FS (29.2%), IGE (18.2%), FS+ with focal seizures (13%) or absence seizures (2.6%), and FS with absence seizures (2.6%). Molecular study of SCN1A, SCN2A, SCN1B, and GABRG2 did not reveal any mutation. Results of our study and literature review indicate that mutations of SCN1A, SCN2A, SCN1B, and GABRG2 in patients with GEFS+ are rare.
The most frequently observed phenotypes matched those reported in families with mutations of the SCN1A, SCN1B, and GABRG2 genes. IGE and GEFS+ may overlap in some families, suggesting a shared genetic mechanism. The observation that 13% of affected individuals had focal epilepsy confirms previously reported rates and should prompt a reformulation of the "GEFS+" concept to include focal epileptogenesis.
我们描述了7个患有热性惊厥附加症伴全面性癫痫(GEFS+)的意大利家族,其中排除了SCN1A、SCN1B和GABRG2基因的突变,并将其临床谱与先前报道的具有已知突变的GEFS+的临床谱进行比较。
我们对7个家族(167名个体)进行了临床研究。分子研究包括通过变性高效液相色谱(DHPLC)分析SCN1A和SCN1B外显子的聚合酶链反应(PCR)片段,并对所有家族中的GABRG2进行直接测序。我们在一个大家系中通过连锁分析排除了SCN1A、SCN1B和GABRG2基因,并对一个新生儿-婴儿期起病的癫痫家族中的SCN2A进行了直接测序。我们将我们家族中观察到的癫痫表型与携带SCN1A、SCN1B和GABRG2突变的GEFS+家族的表型进行比较,并通过回顾所有已发表的研究估计这些基因在GEFS+病例中的突变百分比。
遗传方式为常染色体显性遗传,外显率为69%。41名个体患有癫痫:29名具有与GEFS+一致的表型;7名患有特发性全面性癫痫(IGE);3名癫痫类型无法分类;2名被认为是表型模拟。临床表型包括热性惊厥附加症(FS+,29.2%)、热性惊厥(FS,29.2%)、IGE(18.2%)、伴有局灶性发作(13%)或失神发作(2.6%)的FS+以及伴有失神发作(2.6%)的FS。SCN1A、SCN2A、SCN1B和GABRG2的分子研究未发现任何突变。我们的研究结果和文献综述表明,GEFS+患者中SCN1A、SCN2A、SCN1B和GABRG2的突变很少见。
最常观察到的表型与报道的携带SCN1A、SCN1B和GABRG2基因突变的家族中的表型相符。IGE和GEFS+在一些家族中可能重叠,提示存在共同的遗传机制。13%的受累个体患有局灶性癫痫这一观察结果证实了先前报道的发生率,应促使重新定义“GEFS+”概念以纳入局灶性癫痫发生机制。